SAGE-217, a novel modulator of γ-aminobutyric acid–A (GABAA), reduced depressive symptoms in patients with major depression in a new study.
Investigators compared patients who had major depression and were treated with SAGE-217 to patients who received placebo for a 2-week period. They found that a larger percentage of patients in the SAGE-217 group demonstrated a response to the treatment or remission, compared to those in the placebo group. There were no serious or severe adverse events. The study was published online September 5 in the New England Journal of Medicine.